Adage Capital Partners
CGEM icon

Adage Capital Partners’s Cullinan Oncology CGEM Stock Holding History

Adage Capital Partners’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,030,438
Closed -$12.6M – 858
2024
Q4 		$12.6M Sell
1,030,438
-325,438
-24% -$4.68M 0.02% 548
2024
Q3 		$22.7M Sell
1,355,876
-876,953
-39% -$15.6M 0.04% 423
2024
Q2 		$38.9M Buy
2,232,829
+1,282,829
+135% +$27.3M 0.07% 269
2024
Q1 		$16.2M Buy
+950,000
New +$14.7M 0.03% 506
2023
Q4 		– Sell
-1,150,000
Closed -$10.4M – 869
2023
Q3 		$10.4M Hold
1,150,000
– – 0.02% 553
2023
Q2 		$12.4M Buy
+1,150,000
New +$12.2M 0.03% 525
2021
Q3 		– Sell
-78,000
Closed -$2.01M – 1027
2021
Q2 		$2.01M Sell
78,000
-263,731
-77% -$8.11M ﹤0.01% 880
2021
Q1 		$14.2M Buy
+341,731
New +$13.9M 0.03% 569

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners's CGEM Position: Q1 2025 in Review

Adage Capital Partners sold out of Cullinan Oncology (CGEM) in Q1 2025, closing a stake of 1,030,438 shares — an estimated $12.6M sold.

Adage Capital Partners first reported a position in CGEM in Q1 2021 and held it in 8 quarters. The position peaked at $38.9M in Q2 2024. 148 funds tracked by Wall St. Rank hold CGEM as of Q1 2025.

  • Adage Capital Partners reported no remaining Cullinan Oncology position as of Q1 2025 after selling out during the quarter.
  • Adage Capital Partners sold 1,030,438 Cullinan Oncology shares in Q1 2025, an estimated $12.6M.
  • Adage Capital Partners first reported a position in Cullinan Oncology in Q1 2021 and held it in 8 quarters.
  • Adage Capital Partners's Cullinan Oncology position peaked at $38.9M in Q2 2024.
  • 148 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.